ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/Other/SuO-Glu-Val-Cit-PAB-MMAE
C67H103N11O17
1334.6 g/mol
Other

SuO-Glu-Val-Cit-PAB-MMAE

CAS1895916-24-1
Category
Other
Compound Class
Peptide
Primary Use
antibody-drug conjugate linker payload

This compound is an antibody-drug conjugate linker payload, composed of a cleavable linker and the antimitotic agent monomethyl auristatin E (MMAE). It is designed for use in the development of targeted cancer therapeutics.

research reagent for antibody-drug conjugate developmentcompound used in pharmaceutical manufacturing of targeted therapies

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing SuO-Glu-Val-Cit-PAB-MMAE?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

StrongStructure SimilarSimilarity 0.98

SC-VC-PAB-MMAE

CAS2259318-46-0

research compound

SimilarStructure SimilarSimilarity 0.82

[4-[[(2S)-2-[[(2S)-2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate

CAS2684216-48-4

pharmaceutical raw material

SimilarStructure SimilarSimilarity 0.81

VC-PAB-MMAE

CAS644981-35-1

pharmaceutical intermediate

SimilarStructure SimilarSimilarity 0.80

[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[3-[2-[2-[2-[2-[2-[2-[2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate

CAS2353409-69-3

pharmaceutical raw material

ReferenceSame Category

Acetyl tyrosylarginine cetyl ester

CAS196604-48-5

cosmetic ingredient

ReferenceSame Category

1-[(4-Chlorophenyl)(phenyl)methyl]-4-nitrosopiperazine

CAS2005-04-1

nitrosamine impurity reference standard

ReferenceSame Category

MMAE-SMCC

CAS2021179-11-1

antibody-drug conjugate linker-payload

ReferenceSame Category

5-Amino-N,N'-bis(2,3-dihydroxypropyl)isophthalamide

CAS203515-86-0

research compound

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more
Identifiers
IUPAC Name

(2,5-dioxopyrrolidin-1-yl) 5-[[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-[[[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-methylcarbamoyl]oxymethyl]anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoate

InChIKey

QULAXLHJSKOZMO-FBMBWUFNSA-N

SMILES

CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)CCCC(=O)ON4C(=O)CCC4=O

Synonyms (3)
  • OSU-VC-PAB-MMAE
  • OSu-Glu-vc-PAB-MMAE
  • SuO-Glu-Val-Cit-PAB-MMAE

Sourcing SuO-Glu-Val-Cit-PAB-MMAE?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→